Track topics on Twitter Track topics that are important to you
Genentech, a member of the Roche Group, has agreed to exclusively license and develop Kineta's α9/α10 nicotinic acetylcholine receptor (nAChR) antagonists as targets for a non-opioid treatment for chronic pain, through a collaboration that Kineta said today could generate for it up to $359 million-plus. The α9/α10 nAChR antagonists could emerge as novel targets for treating chronic neuropathic pain, Kineta said, citing preclinical data showing that investigational compounds that specifically target the receptor reduced pain behaviors in animal models and demonstrated disease-modifying effects, including reduced inflammation and nerve protection at the site of injury. “The α9α10 nAChR represents a mechanistically distinctive target for modifying the disease course of chronic pain. Presently available pain medications act on a limited number of pharmacological targets that treat, but do not prevent, disease progression,” University of Utah researchers Baldomera M. Olivera, Ph.D., and J. Michael McIntosh, M.D., and colleagues, concluded in ...
Original Article: Genentech, Kineta to Partner on Non-Opioid Pain TreatmentsNEXT ARTICLE
Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...
An anesthesiologist (US English) or anaesthetist (British English) is a physician trained in anesthesia and perioperative medicine. Anesthesiologists are physicians who provide medical care to patients in a wide variety of (usually acute) situations. ...